Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
217 stopped studies mapped to Pancreatic Carcinoma and descendants · 94% state a reason
Over the 217 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02414100 | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With… | — | withdrawn | Apr 10, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | No subjects were enrolled. Study team was not able to grow cell lines for the tumors. | Enrollment / accrual |
| NCT03374852 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced… | Phase 2 | withdrawn | Dec 15, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | PI Left institution on 8/6/2018 and study has been final reported with IRB. Never opened to accrual | Investigator |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Phase 1 | terminated | Feb 21, 2023 | Mirati Therapeutics Inc. | Formulation challenges | Other (stated, no rule matched) |
| NCT05494866 | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage…(IntenSify) | Phase 1 | terminated | Aug 10, 2022 | German Cancer Research Center | lack of efficacy paired with high toxicity | Safety / toxicity |
| NCT00881621 | Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer | Phase 2 | terminated | Apr 15, 2009 | Georgetown University | slow enrollment | Enrollment / accrual |
| NCT03822936 | Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas…(PIOPPO) | Phase 2 | terminated | Jan 30, 2019 | CNAO National Center of Oncological Hadrontherapy | The study was early closed due to low accrual in August 2022. | Enrollment / accrual |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small… | Phase 1 | terminated | Nov 30, 2022 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory… | Phase 2 | terminated | Nov 9, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT06206876 | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | withdrawn | Jan 16, 2024 | Roswell Park Cancer Institute | never opened | Other (stated, no rule matched) |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or… | Phase 1 | terminated | Feb 2, 2016 | Mayo Clinic | lack of funding | Funding |
| NCT05546411 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | Phase 2 | terminated | Sep 19, 2022 | Kimberly Perez, MD | Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are… | Drug supply |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT04136769 | Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for…(PREVADER) | N/A | terminated | Oct 23, 2019 | Ulrich Ronellenfitsch, MD | Substantial delays in recruitment | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT01318642 | Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | Phase 2 | terminated | Mar 18, 2011 | NantBioScience, Inc. | NCT01318642: Planned independent DMC Interim review: ended for futility | Efficacy / futility |
| NCT05056805 | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of… | N/A | withdrawn | Sep 27, 2021 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine… | Phase 1 / Phase 2 | withdrawn | Nov 9, 2022 | University of Chicago | 0 enrollment | Enrollment / accrual |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 19, 2018 | OBI Pharma, Inc | Little evidence of clinical activity in tumor types enrolled | Enrollment / accrual |
| NCT04536077 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Phase 2 | terminated | Sep 2, 2020 | Washington University School of Medicine | Celldex decision | Other (stated, no rule matched) |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | Phase 2 | withdrawn | Oct 31, 2023 | Case Comprehensive Cancer Center | PI left the institution | Investigator |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of… | Phase 2 | withdrawn | May 3, 2024 | OHSU Knight Cancer Institute | Sponsor withdrawal | Other (stated, no rule matched) |
| NCT03956056 | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical… | Phase 1 | terminated | May 20, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT04833959 | Pilot Study of 89-Zr Panitumumab in Pancreas Cancer | Phase 1 | withdrawn | Apr 6, 2021 | Stanford University | Business Decision | Sponsor / business decision |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | N/A | withdrawn | Oct 14, 2020 | Medical University of Graz | Covid19 Pandemia | COVID-19 / pandemic |
| NCT04843306 | Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients | N/A | terminated | Apr 13, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Technical difficulties that were not able to be resolved. | Other (stated, no rule matched) |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects…(SLC-0111-17-01) | Phase 1 / Phase 2 | terminated | Mar 1, 2018 | British Columbia Cancer Agency | Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the… | Enrollment / accrual |
| NCT04390243 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a… | Phase 2 | terminated | May 15, 2020 | Academic and Community Cancer Research United | Slow accrual | Enrollment / accrual |
| NCT06341725 | EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging | — | terminated | Apr 2, 2024 | Paolo Giorgio Arcidiacono, MD | no patients with inclusion criteria | Other (stated, no rule matched) |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or… | Phase 1 / Phase 2 | terminated | Dec 18, 2017 | Georgetown University | Study closed due to lack of enrollment. | Enrollment / accrual |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT03397342 | MRI Only Radiation Therapy With CPAP | N/A | terminated | Jan 12, 2018 | Albert Einstein College of Medicine | Study terminated prematurely well short of enrollment target. Only 5 health participants were… | Enrollment / accrual |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With… | Phase 1 | terminated | Aug 6, 2019 | Patrick Joseph Loehrer Sr. | Unable to proceed due to Neulasta difficulties and other complications. | Other (stated, no rule matched) |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in… | Phase 1 | terminated | May 15, 2018 | Ipsen | Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Safety / toxicity |
| NCT05193604 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects… | Phase 1 | terminated | Jan 18, 2022 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Terminated due to the adjustment of sponsor's development strategies and pipeline. | Sponsor / business decision |
| NCT05702385 | Clinical Utility Study for Exo-PDAC | N/A | withdrawn | Jan 27, 2023 | Qure Healthcare, LLC | The study sponsor did not wish to proceed with the study | Other (stated, no rule matched) |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable… | Phase 2 | terminated | Jul 12, 2013 | Albert Einstein College of Medicine | Study was terminated due to slower than anticipated accrual | Enrollment / accrual |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic…(RELIANT) | Phase 3 | terminated | Apr 1, 2020 | Corcept Therapeutics | The independent data monitoring committee found no safety issues, however the observed response… | Safety / toxicity |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal… | Phase 2 | terminated | Sep 25, 2020 | Zhen Wang, MD | Slow accrual | Enrollment / accrual |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Jul 30, 2021 | Aravive, Inc. | Due to business reasons | Sponsor / business decision |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | Phase 2 | terminated | Mar 9, 2015 | Case Comprehensive Cancer Center | PI discretion based on low accrual | Enrollment / accrual |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 2, 2025source: clinicaltrials